Enhabit, Inc. Logo
US29332G1022
A3DNM9
EHAB

Enhabit, Inc.

Loading quotes...

Forecast

The analysts' average price target is €11.89 (+1.62%). The median is €12.13 (+3.68%).

Buy
  2
Hold
  8
Sell
  1

  • Enhabit to be acquired for $1.10 billion at $13.80, creating near-term floor

    Kinderhook Industries agreed to buy Enhabit for $13.80 per share in an approximately $1.10 billion deal expected to close in Q2 2026, giving the stock a defined acquisition floor. Enhabit has surged 48.16% year-to-date and 60.14% over the past year, while hospice revenue grew 10% in Q4 2025 and full-year operating cash flow rose 38.1% to $70.7 million. Home health admissions increased 7.3%, cost per patient day fell 3.5%, and leverage improved to 3.9x, underpinning operational and balance-sheet improvement ahead of the close. » More on finance.yahoo.com


  • Enhabit to be acquired by Kinderhook for about $1.1 billion

    Kinderhook Industries is acquiring Enhabit in a transaction valued at about $1.1 billion. Shareholders will receive $13.80 per share in cash, representing a premium of roughly 24% to Friday's closing price. The deal is expected to close in the second quarter of 2026 and triggered a premarket rise in Enhabit’s stock of about 22.5%. » More on de.investing.com


  • Enhabit expects better quarter: consensus EPS at $0.142

    Analyst consensus expects Enhabit to report earnings of $0.142 per share for the quarter ended December 31, 2025, versus -$0.920 in the year-ago quarter. Revenue is expected on average to be $270.6 million (prior year $258.2 million). For the fiscal year analysts forecast a mean EPS of $0.563 and revenue of about $1.06 billion versus $1.03 billion in the prior year. » More on finanzen.net

Financials

In the last quarter, Enhabit, Inc. had revenue of €228.76M and net profit of €16.59M
(EUR) March 2026
YoY
Revenue 228.76M 4.78%
Gross profit 108.85M 9.21%
Net profit 16.59M 0.81%
EBITDA 32.48M 15.32%

Fundamentals

Metric Value
Market capitalization
€621.23M
Number of shares
51.23M
52-week high/low
€12.50 - €5.69
Dividends No
Beta
0.96
P/E ratio
-230.00
PEG ratio
-0.69
P/B ratio
1.28
P/S ratio
0.66

Company profile

Enhabit, Inc. bietet in den Vereinigten Staaten hĂ€usliche Gesundheits- und Hospizdienste an. Die hĂ€uslichen Pflegedienste umfassen PatientenaufklĂ€rung, Schmerzmanagement, Wundversorgung und Verbandswechsel, kardiale Rehabilitation, Infusionstherapie, pharmazeutische Verabreichung und qualifizierte Beobachtungs- und Beurteilungsdienste; Praxen zur Behandlung chronischer Krankheiten und ZustĂ€nde, einschließlich Diabetes, Bluthochdruck, Arthritis, Alzheimer-Krankheit, SehschwĂ€che, Spinalkanalstenose, Parkinson-Krankheit, Osteoporose, komplexe Wundversorgung und chronische Schmerzen, zusammen mit krankheitsspezifischen PlĂ€nen fĂŒr Patienten mit Diabetes, Herzinsuffizienz, nach orthopĂ€dischen Operationen oder Verletzungen und Atemwegserkrankungen; und Physio-, Arbeits- und Sprachtherapeuten bieten Therapiedienstleistungen an. DarĂŒber hinaus bietet das Unternehmen Hospizdienste an, darunter Schmerz- und Symptombehandlung, Palliativ- und ErnĂ€hrungsberatung, Besuche von Sozialarbeitern, spirituelle Beratung und Trauerbegleitung, um die individuellen körperlichen, emotionalen, spirituellen und psychosozialen BedĂŒrfnisse von unheilbar kranken Patienten und ihren Familien zu erfĂŒllen. Am 31. MĂ€rz 2022 war das Unternehmen in 252 ambulanten Pflegediensten und 99 Hospizdiensten in 34 Bundesstaaten tĂ€tig. Das Unternehmen war frĂŒher unter dem Namen Encompass Health Home Health Holdings, Inc. bekannt und Ă€nderte im MĂ€rz 2022 seinen Namen in Enhabit, Inc. Enhabit, Inc. wurde im Jahr 2014 gegrĂŒndet und hat seinen Hauptsitz in Dallas, Texas. Ab dem 1. Juli 2022 ist Enhabit, Inc. als eigenstĂ€ndiges Unternehmen tĂ€tig.

Name
Enhabit, Inc.
CEO
Barbara Ann Jacobsmeyer
Headquarters Dallas, tx
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
06/23/2022
Employees 10,600

Ticker symbols

Exchange Symbol
NYSE
EHAB
Frankfurt
X34.F
DĂŒsseldorf
X34.DU
đŸȘ

Parqet  uses cookies. Learn more